drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00872 | DB08912 | 1,080 | 1,040 | [
"DDInter438",
"DDInter462"
] | Conivaptan | Dabrafenib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1080,
24,
1040
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1080,
21,
28779
],
[
28779,
60,
1040
]
],
[
[
1080,
63,
168
],
[
16... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Conivaptan (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Dabrafenib (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bort... |
DB00775 | DB08901 | 1,226 | 1,468 | [
"DDInter1818",
"DDInter1492"
] | Tirofiban | Ponatinib | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1226,
25,
1468
]
],
[
[
1226,
21,
29024
],
[
29024,
60,
1468
]
],
[
[
1226,
63,
1230
],
[
1230,
24,
1468
]
],
[
[
1226,
24,
901
],
[
9... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Tirofiban",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (C... | Tirofiban (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Pona... |
DB06210 | DB11967 | 72 | 710 | [
"DDInter631",
"DDInter210"
] | Eltrombopag | Binimetinib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
72,
24,
710
]
],
[
[
72,
24,
1406
],
[
1406,
24,
710
]
],
[
[
72,
24,
1619
],
[
1619,
63,
710
]
],
[
[
72,
63,
700
],
[
700,
24,... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
],
[
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapa... |
DB01041 | DB01394 | 770 | 1,554 | [
"DDInter1789",
"DDInter431"
] | Thalidomide | Colchicine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
770,
24,
1554
]
],
[
[
770,
63,
717
],
[
717,
40,
1554
]
],
[
[
770,
6,
6365
],
[
6365,
45,
1554
]
],
[
[
770,
7,
2900
],
[
2900,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide (Compound) resembles Colchicine (Compound)
Thalidomide (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Colchicine (Compound)
Thalidomide (Compound) upregulates NFKBIA (Gene) a... |
DB01215 | DB08900 | 1,418 | 1,162 | [
"DDInter677",
"DDInter1753"
] | Estazolam | Teduglutide | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that te... | Moderate | 1 | [
[
[
1418,
24,
1162
]
],
[
[
1418,
40,
1119
],
[
1119,
24,
1162
]
],
[
[
1418,
1,
481
],
[
481,
24,
1162
]
],
[
[
1418,
63,
1101
],
[
1101,... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teduglutide"
]
],
[
[
"Estazolam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may caus... | Estazolam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide
Estazolam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Tedu... |
DB01577 | DB09038 | 1,529 | 1,450 | [
"DDInter1161",
"DDInter636"
] | Metamfetamine | Empagliflozin | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1529,
24,
1450
]
],
[
[
1529,
24,
659
],
[
659,
63,
1450
]
],
[
[
1529,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
1529,
74,
1445
],
[
1445... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lisp... |
DB00444 | DB15965 | 63 | 1,330 | [
"DDInter1765",
"DDInter1270"
] | Teniposide | Naxitamab | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
63,
24,
1330
]
],
[
[
63,
24,
14
],
[
14,
24,
1330
]
],
[
[
63,
63,
10
],
[
10,
24,
1330
]
],
[
[
63,
25,
770
],
[
770,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapson... |
DB00544 | DB10316 | 970 | 334 | [
"DDInter757",
"DDInter1248"
] | Fluorouracil | Mumps virus strain B level jeryl lynn live antigen | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
970,
25,
334
]
],
[
[
970,
64,
1057
],
[
1057,
25,
334
]
],
[
[
970,
24,
328
],
[
328,
25,
334
]
],
[
[
970,
25,
908
],
[
908,
2... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Fluorouracil may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Mercapt... |
DB08815 | DB09054 | 154 | 384 | [
"DDInter1104",
"DDInter905"
] | Lurasidone | Idelalisib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
154,
25,
384
]
],
[
[
154,
63,
222
],
[
222,
23,
384
]
],
[
[
154,
64,
600
],
[
600,
24,
384
]
],
[
[
154,
63,
761
],
[
761,
24,... | [
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Lurasidone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may caus... |
DB00708 | DB00877 | 1,454 | 629 | [
"DDInter1718",
"DDInter1678"
] | Sufentanil | Sirolimus | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1454,
24,
629
]
],
[
[
1454,
6,
8374
],
[
8374,
45,
629
]
],
[
[
1454,
21,
28921
],
[
28921,
60,
629
]
],
[
[
1454,
24,
1476
],
[
1476... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Sufentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Sufentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Sufentanil (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigat... |
DB00313 | DB08896 | 556 | 292 | [
"DDInter1913",
"DDInter1576"
] | Valproic acid | Regorafenib | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
556,
24,
292
]
],
[
[
556,
6,
6017
],
[
6017,
45,
292
]
],
[
[
556,
21,
29122
],
[
29122,
60,
292
]
],
[
[
556,
63,
1560
],
[
1560,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Comp... | Valproic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Valproic acid (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Regorafenib (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases wh... |
DB01058 | DB11901 | 978 | 913 | [
"DDInter1510",
"DDInter107"
] | Praziquantel | Apalutamide | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
978,
25,
913
]
],
[
[
978,
24,
1320
],
[
1320,
63,
913
]
],
[
[
978,
24,
1678
],
[
1678,
24,
913
]
],
[
[
978,
62,
510
],
[
510,
... | [
[
[
"Praziquantel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagoli... | Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad and Lesinu... |
DB09118 | DB11921 | 1,580 | 1,019 | [
"DDInter1711",
"DDInter492"
] | Stiripentol | Deflazacort | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1580,
25,
1019
]
],
[
[
1580,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
1580,
63,
761
],
[
761,
24,
1019
]
],
[
[
1580,
63,
723
],
[
723,
... | [
[
[
"Stiripentol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucapari... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxa... |
DB00008 | DB09498 | 491 | 810 | [
"DDInter1407",
"DDInter1715"
] | Peginterferon alfa-2a | Strontium chloride Sr-89 | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
491,
24,
810
]
],
[
[
491,
24,
1555
],
[
1555,
24,
810
]
],
[
[
491,
24,
1060
],
[
1060,
63,
810
]
],
[
[
491,
25,
976
],
[
976,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases... |
DB00855 | DB01128 | 213 | 918 | [
"DDInter72",
"DDInter204"
] | Aminolevulinic acid | Bicalutamide | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
213,
25,
918
]
],
[
[
213,
21,
29232
],
[
29232,
60,
918
]
],
[
[
213,
25,
1247
],
[
1247,
23,
918
]
],
[
[
213,
25,
392
],
[
392,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is... | Aminolevulinic acid (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Bicalutamide (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when tak... |
DB00808 | DB01088 | 1,605 | 714 | [
"DDInter916",
"DDInter908"
] | Indapamide | Iloprost | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1605,
24,
714
]
],
[
[
1605,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1605,
24,
1450
],
[
1450,
63,
714
]
],
[
[
1605,
40,
811
],
[
811,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Emp... |
DB00470 | DB00877 | 530 | 629 | [
"DDInter601",
"DDInter1678"
] | Dronabinol | Sirolimus | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
530,
24,
629
]
],
[
[
530,
6,
4973
],
[
4973,
45,
629
]
],
[
[
530,
21,
28921
],
[
28921,
60,
629
]
],
[
[
530,
24,
1476
],
[
1476,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronabinol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Dronabinol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatin... |
DB05239 | DB11799 | 866 | 627 | [
"DDInter425",
"DDInter205"
] | Cobimetinib | Bictegravir | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
866,
24,
627
]
],
[
[
866,
24,
1362
],
[
1362,
24,
627
]
],
[
[
866,
63,
478
],
[
478,
24,
627
]
],
[
[
866,
64,
600
],
[
600,
2... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotini... |
DB00261 | DB00450 | 702 | 78 | [
"DDInter93",
"DDInter603"
] | Anagrelide | Droperidol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Major | 2 | [
[
[
702,
25,
78
]
],
[
[
702,
25,
1300
],
[
1300,
40,
78
]
],
[
[
702,
25,
1568
],
[
1568,
1,
78
]
],
[
[
702,
21,
28921
],
[
28921,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u}... | Anagrelide may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Pimozide and Pimozide (Compound) resembles Droperidol (Compound)
Anagrelide (Compound) causes Diz... |
DB01181 | DB01403 | 1,532 | 9 | [
"DDInter906",
"DDInter1175"
] | Ifosfamide | Methotrimeprazine | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1532,
24,
9
]
],
[
[
1532,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1532,
63,
1164
],
[
1164,
1,
9
]
],
[
[
1532,
63,
401
],
[
401,
24... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles M... |
DB00242 | DB09312 | 1,064 | 967 | [
"DDInter392",
"DDInter103"
] | Cladribine | Antilymphocyte immunoglobulin (horse) | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Major | 2 | [
[
[
1064,
25,
967
]
],
[
[
1064,
63,
1461
],
[
1461,
62,
967
]
],
[
[
1064,
25,
1683
],
[
1683,
24,
967
]
],
[
[
1064,
25,
1531
],
[
1531,... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse)
Cladribine may lead to a major life threatening interaction when taken with Ustekinumab a... |
DB00372 | DB09237 | 999 | 1,586 | [
"DDInter1793",
"DDInter1045"
] | Thiethylperazine | Levamlodipine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
999,
24,
1586
]
],
[
[
999,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
999,
24,
549
],
[
549,
24,
1586
]
],
[
[
999,
25,
593
],
[
593,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dapa... |
DB00889 | DB01191 | 1,133 | 1,039 | [
"DDInter840",
"DDInter518"
] | Granisetron | Dexfenfluramine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
1133,
25,
1039
]
],
[
[
1133,
6,
12523
],
[
12523,
45,
1039
]
],
[
[
1133,
63,
479
],
[
479,
23,
1039
]
],
[
[
1133,
24,
673
],
[
673,... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Granisetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"... | Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dexfenfluramine
Granisetro... |
DB00188 | DB09061 | 168 | 1,627 | [
"DDInter222",
"DDInter284"
] | Bortezomib | Cannabidiol | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
168,
24,
1627
]
],
[
[
168,
24,
723
],
[
723,
23,
1627
]
],
[
[
168,
24,
760
],
[
760,
62,
1627
]
],
[
[
168,
23,
660
],
[
660,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicis... |
DB00519 | DB01168 | 1,638 | 1,053 | [
"DDInter1843",
"DDInter1526"
] | Trandolapril | Procarbazine | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1638,
24,
1053
]
],
[
[
1638,
24,
848
],
[
848,
40,
1053
]
],
[
[
1638,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1638,
24,
104
],
[
104... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Trandolapril (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Trandolapril may cause a moderate intera... |
DB00486 | DB00964 | 1,614 | 1,617 | [
"DDInter1253",
"DDInter110"
] | Nabilone | Apraclonidine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
1614,
24,
1617
]
],
[
[
1614,
24,
1020
],
[
1020,
1,
1617
]
],
[
[
1614,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
1614,
21,
28975
],
[
28... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apraclonidine (Compound)
... |
DB05773 | DB13007 | 1,047 | 1,060 | [
"DDInter1848",
"DDInter642"
] | Trastuzumab emtansine | Enfortumab vedotin | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1047,
24,
1060
]
],
[
[
1047,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1047,
63,
14
],
[
14,
24,
1060
]
],
[
[
1047,
25,
1468
],
[
1468,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00909 | DB01619 | 306 | 830 | [
"DDInter1971",
"DDInter1441"
] | Zonisamide | Phenindamine | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Major | 2 | [
[
[
306,
25,
830
]
],
[
[
306,
25,
537
],
[
537,
40,
830
]
],
[
[
306,
64,
1219
],
[
1219,
40,
830
]
],
[
[
306,
64,
13
],
[
13,
24,... | [
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenindamine"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (... | Zonisamide may lead to a major life threatening interaction when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Zonisamide may lead to a major life threatening interaction when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Zonisamide may lead to a major... |
DB00060 | DB11363 | 912 | 1,276 | [
"DDInter947",
"DDInter39"
] | Interferon beta-1a | Alectinib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
912,
24,
1276
]
],
[
[
912,
63,
305
],
[
305,
24,
1276
]
],
[
[
912,
24,
1011
],
[
1011,
24,
1276
]
],
[
[
912,
24,
242
],
[
242,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Interferon beta-1a may cause a moderate interaction that could exac... |
DB00559 | DB00563 | 152 | 663 | [
"DDInter223",
"DDInter1174"
] | Bosentan | Methotrexate | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
152,
24,
663
]
],
[
[
152,
21,
29215
],
[
29215,
60,
663
]
],
[
[
152,
24,
126
],
[
126,
62,
663
]
],
[
[
152,
24,
1501
],
[
1501,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Bosentan",
"{u} (Compound) causes {v} (Side Effect)",
"Ecchymosis"
],
[
"Ecchymosis",
"{u} (Side Effect) is caus... | Bosentan (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Methotrexate (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate
... |
DB00308 | DB06603 | 347 | 39 | [
"DDInter901",
"DDInter1387"
] | Ibutilide | Panobinostat | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
347,
25,
39
]
],
[
[
347,
23,
112
],
[
112,
23,
39
]
],
[
[
347,
24,
455
],
[
455,
24,
39
]
],
[
[
347,
24,
720
],
[
720,
63,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salm... |
DB00661 | DB11921 | 122 | 1,019 | [
"DDInter1928",
"DDInter492"
] | Verapamil | Deflazacort | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
122,
25,
1019
]
],
[
[
122,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
122,
24,
761
],
[
761,
24,
1019
]
],
[
[
122,
62,
1512
],
[
1512,
... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxaglip... |
DB01211 | DB11581 | 609 | 1,456 | [
"DDInter393",
"DDInter1926"
] | Clarithromycin | Venetoclax | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
609,
25,
1456
]
],
[
[
609,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
609,
25,
241
],
[
241,
63,
1456
]
],
[
[
609,
24,
466
],
[
466,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Clarithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Clarithromycin may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may cause a moderat... |
DB11248 | DB15762 | 1,193 | 725 | [
"DDInter1965",
"DDInter1644"
] | Zinc gluconate | Satralizumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Minor | 0 | [
[
[
1193,
23,
725
]
],
[
[
1193,
62,
629
],
[
629,
24,
725
]
],
[
[
1193,
23,
270
],
[
270,
24,
725
]
],
[
[
1193,
62,
1066
],
[
1066,
... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Satralizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sirolimus"
],
... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and O... |
DB09034 | DB11967 | 1,313 | 710 | [
"DDInter1733",
"DDInter210"
] | Suvorexant | Binimetinib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1313,
24,
710
]
],
[
[
1313,
64,
1593
],
[
1593,
24,
710
]
],
[
[
1313,
24,
951
],
[
951,
24,
710
]
],
[
[
1313,
24,
1619
],
[
1619,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Suvorexant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotini... | Suvorexant may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cau... |
DB00741 | DB00903 | 167 | 1,680 | [
"DDInter885",
"DDInter686"
] | Hydrocortisone | Etacrynic acid | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
167,
24,
1680
]
],
[
[
167,
18,
2023
],
[
2023,
46,
1680
]
],
[
[
167,
21,
28882
],
[
28882,
60,
1680
]
],
[
[
167,
24,
1479
],
[
1479... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) downregulates {v} (Gene)",
"RAP1GAP"
],
[
"RAP1GAP",
"{u} (Gene) is upr... | Hydrocortisone (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Etacrynic acid (Compound)
Hydrocortisone (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Etacrynic acid (Compound)
Hydrocortisone may cause a moderate interact... |
DB00902 | DB01041 | 104 | 770 | [
"DDInter1168",
"DDInter1789"
] | Methdilazine | Thalidomide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
104,
24,
770
]
],
[
[
104,
24,
849
],
[
849,
63,
770
]
],
[
[
104,
63,
1533
],
[
1533,
24,
770
]
],
[
[
104,
75,
684
],
[
684,
2... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone and E... |
DB00270 | DB14568 | 1,428 | 982 | [
"DDInter993",
"DDInter1000"
] | Isradipine | Ivosidenib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1428,
24,
982
]
],
[
[
1428,
24,
1101
],
[
1101,
23,
982
]
],
[
[
1428,
1,
1081
],
[
1081,
24,
982
]
],
[
[
1428,
24,
770
],
[
770,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Isradipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could... |
DB00694 | DB06288 | 51 | 607 | [
"DDInter485",
"DDInter77"
] | Daunorubicin | Amisulpride | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
51,
25,
607
]
],
[
[
51,
18,
2475
],
[
2475,
46,
607
]
],
[
[
51,
21,
29232
],
[
29232,
60,
607
]
],
[
[
51,
23,
112
],
[
112,
2... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is upregulated by {v} (Compound)",... | Daunorubicin (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Amisulpride (Compound)
Daunorubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Met... |
DB00673 | DB01218 | 723 | 1,493 | [
"DDInter112",
"DDInter852"
] | Aprepitant | Halofantrine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
723,
25,
1493
]
],
[
[
723,
6,
8374
],
[
8374,
45,
1493
]
],
[
[
723,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
723,
24,
211
],
[
211,
... | [
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Halof... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halofantrine (Compound)
Aprepitant (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when ta... |
DB00627 | DB01276 | 265 | 123 | [
"DDInter1286",
"DDInter706"
] | Niacin | Exenatide | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
265,
24,
123
]
],
[
[
265,
63,
1560
],
[
1560,
24,
123
]
],
[
[
265,
24,
850
],
[
850,
63,
123
]
],
[
[
265,
24,
959
],
[
959,
2... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pe... | Niacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Br... |
DB00686 | DB05578 | 383 | 330 | [
"DDInter1424",
"DDInter1566"
] | Pentosan polysulfate | Ramucirumab | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Moderate | 1 | [
[
[
383,
24,
330
]
],
[
[
383,
24,
765
],
[
765,
24,
330
]
],
[
[
383,
24,
1317
],
[
1317,
25,
330
]
],
[
[
383,
63,
1061
],
[
1061,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"... | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamo... |
DB09118 | DB15091 | 1,580 | 676 | [
"DDInter1711",
"DDInter1901"
] | Stiripentol | Upadacitinib | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
1580,
24,
676
]
],
[
[
1580,
24,
283
],
[
283,
24,
676
]
],
[
[
1580,
63,
1593
],
[
1593,
24,
676
]
],
[
[
1580,
63,
891
],
[
891,
... | [
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Cr... |
DB01589 | DB09085 | 481 | 587 | [
"DDInter1552",
"DDInter1779"
] | Quazepam | Tetracaine | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch. | Moderate | 1 | [
[
[
481,
24,
587
]
],
[
[
481,
40,
1216
],
[
1216,
24,
587
]
],
[
[
481,
1,
905
],
[
905,
24,
587
]
],
[
[
481,
40,
1216
],
[
1216,
... | [
[
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracaine"
]
],
[
[
"Quazepam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate in... | Quazepam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine
Quazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine
Quazep... |
DB00771 | DB01618 | 262 | 776 | [
"DDInter397",
"DDInter1239"
] | Clidinium | Molindone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
262,
24,
776
]
],
[
[
262,
6,
7992
],
[
7992,
45,
776
]
],
[
[
262,
24,
100
],
[
100,
24,
776
]
],
[
[
262,
63,
1442
],
[
1442,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Clidinium",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clidinium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Molindone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Clidinium may ... |
DB01764 | DB06228 | 805 | 792 | [
"DDInter469",
"DDInter1609"
] | Dalfopristin | Rivaroxaban | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
805,
24,
792
]
],
[
[
805,
6,
8374
],
[
8374,
45,
792
]
],
[
[
805,
23,
466
],
[
466,
63,
792
]
],
[
[
805,
25,
1670
],
[
1670,
... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Dalfopristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Dalfoprist... |
DB01246 | DB06616 | 820 | 594 | [
"DDInter45",
"DDInter224"
] | Alimemazine | Bosutinib | A phenothiazine derivative that is used as an antipruritic. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
820,
24,
594
]
],
[
[
820,
6,
8374
],
[
8374,
45,
594
]
],
[
[
820,
7,
4055
],
[
4055,
45,
594
]
],
[
[
820,
7,
7434
],
[
7434,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Alimemazine (Compound) upregulates CHEK2 (Gene) and CHEK2 (Gene) is bound by Bosutinib (Compound)
Alimemazine (Compound) upregulates HSD17B7 (Gene) and HSD17B7 (Gene) is upregulated by Bosutinib (Compound)
Alimemazine (Compoun... |
DB01364 | DB09472 | 22 | 1,383 | [
"DDInter650",
"DDInter1693"
] | Ephedrine | Sodium sulfate | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
22,
24,
1383
]
],
[
[
22,
24,
1482
],
[
1482,
23,
1383
]
],
[
[
22,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
22,
63,
146
],
[
146,
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may... |
DB00334 | DB08882 | 867 | 1,281 | [
"DDInter1326",
"DDInter1070"
] | Olanzapine | Linagliptin | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
867,
24,
1281
]
],
[
[
867,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
867,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
867,
1,
623
],
[
623,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetia... |
DB01033 | DB10583 | 328 | 949 | [
"DDInter1156",
"DDInter415"
] | Mercaptopurine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
328,
24,
949
]
],
[
[
328,
63,
589
],
[
589,
24,
949
]
],
[
[
328,
25,
1377
],
[
1377,
24,
949
]
],
[
[
328,
62,
663
],
[
663,
2... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate disease... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Mercaptopurine may lead to a major life threatening interact... |
DB00374 | DB00774 | 1,061 | 1,577 | [
"DDInter1852",
"DDInter889"
] | Treprostinil | Hydroflumethiazide | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
1061,
24,
1577
]
],
[
[
1061,
24,
359
],
[
359,
40,
1577
]
],
[
[
1061,
24,
504
],
[
504,
1,
1577
]
],
[
[
1061,
7,
2475
],
[
2475,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Comp... |
DB00798 | DB04834 | 1,132 | 276 | [
"DDInter815",
"DDInter1571"
] | Gentamicin | Rapacuronium | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Major | 2 | [
[
[
1132,
25,
276
]
],
[
[
1132,
63,
91
],
[
91,
24,
276
]
],
[
[
1132,
24,
568
],
[
568,
24,
276
]
],
[
[
1132,
64,
1441
],
[
1441,
... | [
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rapacuronium"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomyc... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Rapacuronium
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Cli... |
DB00334 | DB00445 | 867 | 322 | [
"DDInter1326",
"DDInter655"
] | Olanzapine | Epirubicin | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
867,
24,
322
]
],
[
[
867,
7,
8153
],
[
8153,
46,
322
]
],
[
[
867,
7,
5178
],
[
5178,
57,
322
]
],
[
[
867,
23,
112
],
[
112,
6... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Olanzapine",
"{u} (Compound) upregulates {v} (Gene)",
"ADCK3"
],
[
"ADCK3",
"{u} (Gene) is upregulated by {v} (C... | Olanzapine (Compound) upregulates ADCK3 (Gene) and ADCK3 (Gene) is upregulated by Epirubicin (Compound)
Olanzapine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Epirubicin (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00384 | DB11110 | 1,275 | 603 | [
"DDInter1859",
"DDInter1115"
] | Triamterene | Magnesium citrate | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1275,
24,
603
]
],
[
[
1275,
24,
870
],
[
870,
24,
603
]
],
[
[
1275,
23,
1545
],
[
1545,
24,
603
]
],
[
[
1275,
62,
964
],
[
964,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamterene may cause a minor interaction that can limit clinical effects when taken with Oxyt... |
DB01045 | DB11967 | 463 | 710 | [
"DDInter1590",
"DDInter210"
] | Rifampicin | Binimetinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
463,
24,
710
]
],
[
[
463,
25,
1593
],
[
1593,
24,
710
]
],
[
[
463,
63,
883
],
[
883,
24,
710
]
],
[
[
463,
24,
1619
],
[
1619,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotini... | Rifampicin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a... |
DB00526 | DB06603 | 1,555 | 39 | [
"DDInter1355",
"DDInter1387"
] | Oxaliplatin | Panobinostat | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1555,
25,
39
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
39
]
],
[
[
1555,
24,
112
],
[
112,
23,
39
]
],
[
[
1555,
63,
912
],
[
912,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Oxaliplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Su... | Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronida... |
DB00365 | DB01142 | 839 | 1,264 | [
"DDInter842",
"DDInter593"
] | Grepafloxacin | Doxepin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
839,
25,
1264
]
],
[
[
839,
25,
401
],
[
401,
24,
1264
]
],
[
[
839,
23,
112
],
[
112,
23,
1264
]
],
[
[
839,
64,
600
],
[
600,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
... | Grepafloxacin may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole... |
DB08875 | DB12245 | 1,618 | 823 | [
"DDInter262",
"DDInter1863"
] | Cabozantinib | Triclabendazole | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1618,
25,
823
]
],
[
[
1618,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1618,
25,
1612
],
[
1612,
24,
823
]
],
[
[
1618,
64,
1010
],
[
1010,... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Cabozantinib may lead to a major life threatening interaction when taken with Fostemsavir and Fos... |
DB00470 | DB00690 | 530 | 1,216 | [
"DDInter601",
"DDInter762"
] | Dronabinol | Flurazepam | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
530,
24,
1216
]
],
[
[
530,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
530,
24,
481
],
[
481,
40,
1216
]
],
[
[
530,
63,
902
],
[
902,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Dronab... |
DB10276 | DB11793 | 1,624 | 738 | [
"DDInter1623",
"DDInter1297"
] | Rotavirus vaccine | Niraparib | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Major | 2 | [
[
[
1624,
25,
738
]
],
[
[
1624,
64,
1213
],
[
1213,
24,
738
]
],
[
[
1624,
25,
1619
],
[
1619,
63,
738
]
],
[
[
1624,
25,
351
],
[
351,
... | [
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Rotavirus vaccine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Rotavirus vaccine may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a mode... |
DB01102 | DB01142 | 1,188 | 1,264 | [
"DDInter114",
"DDInter593"
] | Arbutamine | Doxepin | Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1188,
25,
1264
]
],
[
[
1188,
63,
352
],
[
352,
24,
1264
]
],
[
[
1188,
1,
455
],
[
455,
24,
1264
]
],
[
[
1188,
24,
1511
],
[
1511,
... | [
[
[
"Arbutamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Arbutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
... | Arbutamine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Arbutamine (Compound) resembles Salmeterol (Compound) and Salmeterol may cause a moderate interaction that could exacer... |
DB00843 | DB09065 | 479 | 760 | [
"DDInter583",
"DDInter424"
] | Donepezil | Cobicistat | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Minor | 0 | [
[
[
479,
23,
760
]
],
[
[
479,
63,
1101
],
[
1101,
23,
760
]
],
[
[
479,
23,
1374
],
[
1374,
23,
760
]
],
[
[
479,
62,
723
],
[
723,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Donepezil may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone... |
DB00220 | DB09143 | 798 | 313 | [
"DDInter1276",
"DDInter1701"
] | Nelfinavir | Sonidegib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
798,
25,
313
]
],
[
[
798,
23,
1194
],
[
1194,
23,
313
]
],
[
[
798,
64,
837
],
[
837,
23,
313
]
],
[
[
798,
25,
101
],
[
101,
2... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
... | Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Nelfinavir may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazole may cause a... |
DB00570 | DB04908 | 147 | 1,671 | [
"DDInter1936",
"DDInter741"
] | Vinblastine | Flibanserin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
147,
24,
1671
]
],
[
[
147,
63,
168
],
[
168,
23,
1671
]
],
[
[
147,
24,
741
],
[
741,
63,
1671
]
],
[
[
147,
24,
51
],
[
51,
24... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolap... |
DB00350 | DB00374 | 1,214 | 1,061 | [
"DDInter1226",
"DDInter1852"
] | Minoxidil | Treprostinil | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
1214,
24,
1061
]
],
[
[
1214,
24,
885
],
[
885,
40,
1061
]
],
[
[
1214,
23,
402
],
[
402,
62,
1061
]
],
[
[
1214,
24,
1450
],
[
1450,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Minoxidil may cause a minor interaction that can limit clinical effects when taken with Tadalafil and Tadalafil may cause a minor interaction that can limi... |
DB00445 | DB00691 | 322 | 1,058 | [
"DDInter655",
"DDInter1237"
] | Epirubicin | Moexipril | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
322,
24,
1058
]
],
[
[
322,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
322,
24,
479
],
[
479,
40,
1058
]
],
[
[
322,
24,
663
],
[
663,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Moexipril (Compound)
... |
DB00572 | DB06702 | 85 | 573 | [
"DDInter136",
"DDInter731"
] | Atropine | Fesoterodine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
85,
24,
573
]
],
[
[
85,
24,
211
],
[
211,
1,
573
]
],
[
[
85,
63,
494
],
[
494,
1,
573
]
],
[
[
85,
6,
2720
],
[
2720,
45,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Comp... |
DB00685 | DB06792 | 1,299 | 1,606 | [
"DDInter1887",
"DDInter1023"
] | Trovafloxacin | Lanthanum carbonate | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
1299,
24,
1606
]
],
[
[
1299,
1,
872
],
[
872,
24,
1606
]
],
[
[
1299,
24,
428
],
[
428,
63,
1606
]
],
[
[
1299,
24,
1096
],
[
1096,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} ... | Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a ... |
DB00978 | DB06595 | 739 | 1,491 | [
"DDInter1084",
"DDInter1214"
] | Lomefloxacin | Midostaurin | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
739,
24,
1491
]
],
[
[
739,
62,
112
],
[
112,
23,
1491
]
],
[
[
739,
24,
761
],
[
761,
24,
1491
]
],
[
[
739,
63,
888
],
[
888,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin an... |
DB00384 | DB09156 | 1,275 | 777 | [
"DDInter1859",
"DDInter964"
] | Triamterene | Iopromide | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
1275,
24,
777
]
],
[
[
1275,
63,
1648
],
[
1648,
24,
777
]
],
[
[
1275,
24,
1512
],
[
1512,
25,
777
]
],
[
[
1275,
63,
1645
],
[
1645,... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Dic... |
DB00013 | DB12364 | 1,255 | 1,421 | [
"DDInter1905",
"DDInter200"
] | Urokinase | Betrixaban | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1255,
25,
1421
]
],
[
[
1255,
23,
297
],
[
297,
23,
1421
]
],
[
[
1255,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
1255,
24,
992
],
[
992,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Urokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor... |
DB00434 | DB00831 | 13 | 1,178 | [
"DDInter459",
"DDInter1866"
] | Cyproheptadine | Trifluoperazine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
13,
24,
1178
]
],
[
[
13,
74,
695
],
[
695,
40,
1178
]
],
[
[
13,
24,
146
],
[
146,
40,
1178
]
],
[
[
13,
24,
9
],
[
9,
1,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases... | Cyproheptadine (Compound) resembles Clozapine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00281 | DB06414 | 608 | 655 | [
"DDInter1066",
"DDInter703"
] | Lidocaine | Etravirine | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
608,
24,
655
]
],
[
[
608,
6,
4973
],
[
4973,
45,
655
]
],
[
[
608,
21,
28680
],
[
28680,
60,
655
]
],
[
[
608,
23,
1101
],
[
1101,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Lidocaine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause ... |
DB00031 | DB01105 | 20 | 222 | [
"DDInter1764",
"DDInter1665"
] | Tenecteplase | Sibutramine | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
20,
24,
222
]
],
[
[
20,
25,
802
],
[
802,
63,
222
]
],
[
[
20,
24,
1027
],
[
1027,
24,
222
]
],
[
[
20,
25,
1432
],
[
1432,
24,... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinza... | Tenecteplase may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cau... |
DB09098 | DB11986 | 98 | 484 | [
"DDInter1700",
"DDInter648"
] | Somatrem | Entrectinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
98,
24,
484
]
],
[
[
98,
62,
271
],
[
271,
23,
484
]
],
[
[
98,
24,
466
],
[
466,
62,
484
]
],
[
[
98,
63,
1135
],
[
1135,
23,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Somatrem",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"... | Somatrem may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamid... |
DB00284 | DB00334 | 1,647 | 867 | [
"DDInter11",
"DDInter1326"
] | Acarbose | Olanzapine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Moderate | 1 | [
[
[
1647,
24,
867
]
],
[
[
1647,
24,
695
],
[
695,
40,
867
]
],
[
[
1647,
24,
1616
],
[
1616,
63,
867
]
],
[
[
1647,
23,
1645
],
[
1645,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Olanzapine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerb... |
DB00023 | DB10315 | 305 | 1,137 | [
"DDInter127",
"DDInter1127"
] | Asparaginase Escherichia coli | Measles virus vaccine live attenuated | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
305,
25,
1137
]
],
[
[
305,
24,
617
],
[
617,
24,
1137
]
],
[
[
305,
25,
581
],
[
581,
25,
1137
]
],
[
[
305,
24,
384
],
[
384,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Asparaginase Escherichia coli may lead to a major life threatening... |
DB01069 | DB08893 | 401 | 271 | [
"DDInter1533",
"DDInter1229"
] | Promethazine | Mirabegron | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Moderate | 1 | [
[
[
401,
24,
271
]
],
[
[
401,
24,
371
],
[
371,
40,
271
]
],
[
[
401,
63,
1523
],
[
1523,
40,
271
]
],
[
[
401,
6,
4973
],
[
4973,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Mirabegron (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Mirabegron (Compou... |
DB00307 | DB06448 | 1,101 | 171 | [
"DDInter202",
"DDInter1087"
] | Bexarotene | Lonafarnib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1101,
24,
171
]
],
[
[
1101,
24,
254
],
[
254,
24,
171
]
],
[
[
1101,
24,
310
],
[
310,
63,
171
]
],
[
[
1101,
23,
1051
],
[
1051,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabaz... |
DB00816 | DB12332 | 1,674 | 1,619 | [
"DDInter1346",
"DDInter1626"
] | Orciprenaline | Rucaparib | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1674,
24,
1619
]
],
[
[
1674,
24,
222
],
[
222,
23,
1619
]
],
[
[
1674,
63,
307
],
[
307,
23,
1619
]
],
[
[
1674,
63,
87
],
[
87,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Mo... |
DB00900 | DB08870 | 45 | 850 | [
"DDInter544",
"DDInter228"
] | Didanosine | Brentuximab vedotin | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
45,
24,
850
]
],
[
[
45,
63,
896
],
[
896,
24,
850
]
],
[
[
45,
24,
1142
],
[
1142,
24,
850
]
],
[
[
45,
24,
1468
],
[
1468,
63,... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and O... |
DB00526 | DB01235 | 1,555 | 1,191 | [
"DDInter1355",
"DDInter1054"
] | Oxaliplatin | Levodopa | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1555,
24,
1191
]
],
[
[
1555,
24,
1307
],
[
1307,
40,
1191
]
],
[
[
1555,
24,
1264
],
[
1264,
23,
1191
]
],
[
[
1555,
24,
286
],
[
286... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinic... |
DB09075 | DB11979 | 498 | 1,320 | [
"DDInter621",
"DDInter625"
] | Edoxaban | Elagolix | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
498,
25,
1320
]
],
[
[
498,
63,
1427
],
[
1427,
24,
1320
]
],
[
[
498,
64,
79
],
[
79,
24,
1320
]
],
[
[
498,
24,
913
],
[
913,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",... | Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Edoxaban may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a mo... |
DB06335 | DB09389 | 761 | 517 | [
"DDInter1646",
"DDInter1315"
] | Saxagliptin | Norgestrel | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
761,
24,
517
]
],
[
[
761,
24,
159
],
[
159,
63,
517
]
],
[
[
761,
63,
86
],
[
86,
24,
517
]
],
[
[
761,
24,
129
],
[
129,
24,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole an... |
DB01225 | DB06605 | 500 | 1,409 | [
"DDInter645",
"DDInter108"
] | Enoxaparin | Apixaban | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
500,
25,
1409
]
],
[
[
500,
6,
2832
],
[
2832,
45,
1409
]
],
[
[
500,
21,
28642
],
[
28642,
60,
1409
]
],
[
[
500,
23,
539
],
[
539,
... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Enoxaparin",
"{u} (Compound) binds {v} (Gene)",
"F10"
],
[
"F10",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]... | Enoxaparin (Compound) binds F10 (Gene) and F10 (Gene) is bound by Apixaban (Compound)
Enoxaparin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Apixaban (Compound)
Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor... |
DB00719 | DB03128 | 1,219 | 140 | [
"DDInter149",
"DDInter18"
] | Azatadine | Acetylcholine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken ... | Moderate | 1 | [
[
[
1219,
24,
140
]
],
[
[
1219,
24,
1376
],
[
1376,
24,
140
]
],
[
[
1219,
63,
85
],
[
85,
24,
140
]
],
[
[
1219,
24,
1116
],
[
1116,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylcholine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Atropine a... |
DB00436 | DB00544 | 323 | 970 | [
"DDInter179",
"DDInter757"
] | Bendroflumethiazide | Fluorouracil | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
323,
24,
970
]
],
[
[
323,
21,
28766
],
[
28766,
60,
970
]
],
[
[
323,
40,
1014
],
[
1014,
63,
970
]
],
[
[
323,
63,
1648
],
[
1648,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{... | Bendroflumethiazide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Fluorouracil (Compound)
Bendroflumethiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Bendroflumethi... |
DB00938 | DB11901 | 455 | 913 | [
"DDInter1635",
"DDInter107"
] | Salmeterol | Apalutamide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
455,
24,
913
]
],
[
[
455,
63,
600
],
[
600,
24,
913
]
],
[
[
455,
24,
1237
],
[
1237,
24,
913
]
],
[
[
455,
25,
609
],
[
609,
2... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and C... |
DB12825 | DB15091 | 1,375 | 676 | [
"DDInter1032",
"DDInter1901"
] | Lefamulin | Upadacitinib | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
1375,
24,
676
]
],
[
[
1375,
63,
283
],
[
283,
24,
676
]
],
[
[
1375,
64,
1593
],
[
1593,
24,
676
]
],
[
[
1375,
24,
159
],
[
159,
... | [
[
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Lefamulin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause ... |
DB00619 | DB08865 | 1,419 | 1,593 | [
"DDInter909",
"DDInter448"
] | Imatinib | Crizotinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1419,
24,
1593
]
],
[
[
1419,
6,
5304
],
[
5304,
45,
1593
]
],
[
[
1419,
7,
2507
],
[
2507,
46,
1593
]
],
[
[
1419,
6,
2692
],
[
2692,... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"ABL2"
],
[
"ABL2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Imatinib (Compound) binds ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)
Imatinib (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Crizotinib (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) is upregulated by Crizotinib (Compound)
Imatinib (Compound) downregulates CTSD... |
DB00559 | DB06292 | 152 | 549 | [
"DDInter223",
"DDInter474"
] | Bosentan | Dapagliflozin | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
152,
24,
549
]
],
[
[
152,
24,
1344
],
[
1344,
40,
549
]
],
[
[
152,
6,
8374
],
[
8374,
45,
549
]
],
[
[
152,
21,
29222
],
[
29222,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Bosentan (Compound) causes Hypoglycaemia (Side Effect) and... |
DB00586 | DB13620 | 1,512 | 948 | [
"DDInter537",
"DDInter1499"
] | Diclofenac | Potassium gluconate | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
1512,
24,
948
]
],
[
[
1512,
24,
848
],
[
848,
24,
948
]
],
[
[
1512,
63,
1027
],
[
1027,
24,
948
]
],
[
[
1512,
35,
1338
],
[
1338,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and ... |
DB00204 | DB00983 | 228 | 480 | [
"DDInter580",
"DDInter776"
] | Dofetilide | Formoterol | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
228,
24,
480
]
],
[
[
228,
25,
1148
],
[
1148,
63,
480
]
],
[
[
228,
21,
28963
],
[
28963,
60,
480
]
],
[
[
228,
25,
870
],
[
870,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprena... | Dofetilide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Dofetilide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Formoterol (Compound)
Dofetilide ... |
DB01100 | DB12245 | 1,568 | 823 | [
"DDInter1470",
"DDInter1863"
] | Pimozide | Triclabendazole | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1568,
25,
823
]
],
[
[
1568,
62,
112
],
[
112,
23,
823
]
],
[
[
1568,
64,
1010
],
[
1010,
24,
823
]
],
[
[
1568,
24,
28
],
[
28,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Pimozide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Pimozide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Pimozide may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cau... |
DB01362 | DB04946 | 497 | 924 | [
"DDInter960",
"DDInter907"
] | Iohexol | Iloperidone | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
497,
25,
924
]
],
[
[
497,
64,
1664
],
[
1664,
1,
924
]
],
[
[
497,
64,
519
],
[
519,
40,
924
]
],
[
[
497,
21,
28809
],
[
28809,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} (Com... | Iohexol may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Iohexol may lead to a major life threatening interaction when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compound)
Iohexol (Compound) causes Di... |
DB00031 | DB14276 | 20 | 1,631 | [
"DDInter1764",
"DDInter1892"
] | Tenecteplase | Turmeric | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
20,
23,
1631
]
],
[
[
20,
24,
1018
],
[
1018,
23,
1631
]
],
[
[
20,
64,
1578
],
[
1578,
23,
1631
]
],
[
[
20,
25,
500
],
[
500,
... | [
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Tenecteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause ... |
DB11988 | DB14762 | 270 | 994 | [
"DDInter1321",
"DDInter1602"
] | Ocrelizumab | Risankizumab | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
270,
24,
994
]
],
[
[
270,
62,
1114
],
[
1114,
23,
994
]
],
[
[
270,
63,
4
],
[
4,
24,
994
]
],
[
[
270,
24,
287
],
[
287,
63,
... | [
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
... | Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepes... |
DB00334 | DB11901 | 867 | 913 | [
"DDInter1326",
"DDInter107"
] | Olanzapine | Apalutamide | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
867,
24,
913
]
],
[
[
867,
23,
112
],
[
112,
23,
913
]
],
[
[
867,
63,
600
],
[
600,
24,
913
]
],
[
[
867,
24,
485
],
[
485,
24,... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB01100 | DB01105 | 1,568 | 222 | [
"DDInter1470",
"DDInter1665"
] | Pimozide | Sibutramine | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1568,
24,
222
]
],
[
[
1568,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1568,
18,
4930
],
[
4930,
57,
222
]
],
[
[
1568,
7,
8386
],
[
8386,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Pimozide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Pimozide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Sibutramine (Compound)
Pimozide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Sibutramine (Compound)
Pimozide (Compoun... |
DB00816 | DB06706 | 1,674 | 468 | [
"DDInter1346",
"DDInter985"
] | Orciprenaline | Isometheptene | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1674,
24,
468
]
],
[
[
1674,
24,
480
],
[
480,
24,
468
]
],
[
[
1674,
63,
1100
],
[
1100,
24,
468
]
],
[
[
1674,
35,
1148
],
[
1148,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.